Teva Pharmaceutical Industries (NYSE:TEVA) PT Raised to $17.00

Teva Pharmaceutical Industries (NYSE:TEVA – Free Report) had its target price increased by Barclays from $15.00 to $17.00 in a report published on Monday morning, Benzinga reports. Barclays currently has an overweight rating on the stock. A number of other research analysts have also recently issued reports on TEVA. HSBC began coverage on shares of […]

Related Keywords

Israel ,United States ,America ,Amir Weiss ,Piper Sandler ,Money Concepts Capital Corp ,Securities Exchange Commission ,News Ratings For Teva Pharmaceutical Industries Daily ,Jefferies Financial Group ,Barclays ,Teva Pharmaceutical Industries ,Blue Trust Inc ,Tower Research Capital ,Teva Pharmaceutical Industries Company Profile ,Analyst Recommendations For Teva Pharmaceutical Industries ,Teva Pharmaceutical Industries Stock Down ,Institutional Trading Of Teva Pharmaceutical Industries ,Free Report ,Moderate Buy ,Pharmaceutical Industries Stock Down ,Pharmaceutical Industries ,Get Free Report ,Teva Pharmaceutical ,Exchange Commission ,Concepts Capital Corp ,Research Capital ,Wealth Management ,Blue Trust ,Pharmaceutical Industries Limited ,North America ,Teva Pharmaceutical Industries Daily ,Nyse Teva ,Teva ,Medical ,Boost Price Target ,Barclays Plc ,